Tamsulosin transdermal - Corium International

Drug Profile

Tamsulosin transdermal - Corium International

Alternative Names: Tamsulosin TDS - Corium International

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corium International
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Benign prostatic hyperplasia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia(In volunteers) in Australia (Transdermal, Patch)
  • 18 Oct 2014 Tamsulosin TDS - Corium International is available for licensing as of 18 Oct 2014. http://www.coriumgroup.com/
  • 12 Aug 2014 Phase-I clinical trials in Benign prostatic hyperplasia in Australia (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top